Biohaven Pharmaceutical Holding Company Ltd. (BHVN) and Sierra Oncology Inc. (NASDAQ:SRRA) Contrasting side by side

We are contrasting Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) and Sierra Oncology Inc. (NASDAQ:SRRA) on their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biohaven Pharmaceutical Holding Company Ltd. N/A 0.00 240.92M -5.61 0.00
Sierra Oncology Inc. N/A 0.00 49.65M -0.63 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 provides us the return on assets, return on equity and net margins of both companies.

Net Margins Return on Equity Return on Assets
Biohaven Pharmaceutical Holding Company Ltd. 0.00% -201% -120.6%
Sierra Oncology Inc. 0.00% -38.9% -36.2%

Liquidity

Biohaven Pharmaceutical Holding Company Ltd.’s Current Ratio is 12 while its Quick Ratio is 12. On the competitive side is, Sierra Oncology Inc. which has a 14.7 Current Ratio and a 14.7 Quick Ratio. Sierra Oncology Inc. is better positioned to pay off short and long-term obligations compared to Biohaven Pharmaceutical Holding Company Ltd.

Institutional & Insider Ownership

Roughly 91.4% of Biohaven Pharmaceutical Holding Company Ltd. shares are held by institutional investors while 67.2% of Sierra Oncology Inc. are owned by institutional investors. Biohaven Pharmaceutical Holding Company Ltd.’s share held by insiders are 1.1%. On the other hand, insiders held about 0.1% of Sierra Oncology Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Biohaven Pharmaceutical Holding Company Ltd. 3.76% 23.81% 50.91% 27.74% 45.51% 27.53%
Sierra Oncology Inc. 13.29% 44.12% 15.98% 12.64% -20.33% 48.48%

For the past year Biohaven Pharmaceutical Holding Company Ltd.’s stock price has smaller growth than Sierra Oncology Inc.

Summary

Sierra Oncology Inc. beats on 6 of the 6 factors Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia. The company also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.

Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in preclinical development stage. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.